Erythropoetin (EPO) antibody and antigen (hapten, BSA/OVA conjugated)
Diagnostic anti-Erythropoetin (EPO) antibodies (anti-Erythropoetin, anti-EPO) and diagnostic hapten-carrier conjugates BSA-Erythropoetin (EPO), OVA-Erythropoetin (EPO), KLH-Erythropoetin (EPO) antigens for Hormone disorders EPO detection in ELISA test, competitive ELISA, Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT.
Go to Neurodegenerative diseases diagnostics products collection >>
Product information
Catalog No. | Description | US $ Price (per mg) |
---|---|---|
GMP-SMT-EPO-Ag01 | BSA-Erythropoetin (EPO) | 756 |
GMP-SMT-EPO-Ag02 | OVA-Erythropoetin (EPO) | 756 |
GMP-SMT-EPO-Ab01 | Anti-human Erythropoetin (EPO) mouse monoclonal antibody (mAb) | 1953 |
GMP-SMT-EPO-Ab02 | Anti-human Erythropoetin (EPO) human monoclonal antibody (mAb) | 1953 |
Size: 1mg | 10mg | 100mg
Product Description
Cat No. of Products | GMP-SMT-EPO-Ag01 |
Product Name | BSA-Erythropoetin (EPO) |
Target/Biomarker | Erythropoetin (EPO) |
Expression platform | Synthetic |
Isotypes | NA |
Bioactivity validation | Erythropoetin (EPO) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in EPO level test of Hormone disorders (Anemia, polycythemia or erythrocytosis, hypertension) and related syndrome evaluation. |
Tag | NA |
Products description | Competitive immunoassay-validated hapten-carrier conjugates BSA-Erythropoetin (EPO) / OVA-Erythropoetin (EPO) is Synthetic. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Competitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry. |
Formulation | Supplied as a 0.2 μM filtered solution of PBS,PH7.4. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. of Products | GMP-SMT-EPO-Ag02 |
Product Name | OVA-Erythropoetin (EPO) |
Target/Biomarker | Erythropoetin (EPO) |
Expression platform | Synthetic |
Isotypes | NA |
Bioactivity validation | Erythropoetin (EPO) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in EPO level test of Hormone disorders (Anemia, polycythemia or erythrocytosis, hypertension) and related syndrome evaluation. |
Tag | NA |
Products description | Competitive immunoassay-validated hapten-carrier conjugates BSA-Erythropoetin (EPO) / OVA-Erythropoetin (EPO) is Synthetic. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Competitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry. |
Formulation | Supplied as a 0.2 μM filtered solution of PBS,PH7.4. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. of Products | GMP-SMT-EPO-Ab01 |
Product Name | Anti-human Erythropoetin (EPO) mouse monoclonal antibody (mAb) |
Target/Biomarker | Erythropoetin (EPO) |
Expression platform | Hybridoma |
Isotypes | Mouse IgG |
Bioactivity validation | Erythropoetin (EPO) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in EPO level test of Hormone disorders (Anemia, polycythemia or erythrocytosis, hypertension) and related syndrome evaluation. |
Tag | mFc |
Products description | Competitive immunoassay-validated hapten-carrier conjugates BSA-Erythropoetin (EPO) / OVA-Erythropoetin (EPO) is Synthetic. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Competitive immunoassay validation (Competitive ELISA),Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry. |
Formulation | Supplied as a 0.2 μM filtered solution of PBS,PH7.4. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. of Products | GMP-SMT-EPO-Ab02 |
Product Name | Anti-human Erythropoetin (EPO) human monoclonal antibody (mAb) |
Target/Biomarker | Erythropoetin (EPO) |
Expression platform | Hybridoma |
Isotypes | Mouse IgG |
Bioactivity validation | Erythropoetin (EPO) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in EPO level test of Hormone disorders (Anemia, polycythemia or erythrocytosis, hypertension) and related syndrome evaluation. |
Tag | mFc |
Products description | Competitive immunoassay-validated hapten-carrier conjugates BSA-Erythropoetin (EPO) / OVA-Erythropoetin (EPO) is Synthetic. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Competitive immunoassay validation (Competitive ELISA),Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry. |
Formulation | Supplied as a 0.2 μM filtered solution of PBS,PH7.4. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Validation Data
Click to get more Data / Case study about the product.
Target/Biomarker information
Erythropoietin (EPO) is produced and released into the blood by the kidneys in response to low blood oxygen levels (hypoxemia). The amount of erythropoietin released depends on how low the oxygen level is and the ability of the kidneys to produce erythropoietin. EPO is carried to the bone marrow, where it stimulates production of red blood cells. The hormone is active for a short period of time and then eliminated from the body in the urine. However, if kidneys are damaged and do not produce enough erythropoietin, then too few RBCs are produced and leads to anemic. Similarly, if bone marrow is unable to respond to the stimulation from EPO also become anemic. This can occur with some bone marrow disorders or with chronic diseases, such as rheumatoid arthritis. The erythropoietin production increased with some benign or malignant kidney tumors and with a variety of other cancers, it also produces too many RBCs (polycythemia or erythrocytosis). This can lead to an increase in the blood’s thickness (viscosity) and sometimes to high blood pressure (hypertension), blood clots (thrombosis), heart attack, or stroke. Rarely, polycythemia is caused by a bone marrow disorder called polycythemia vera, not by increased erythropoietin.
About GDU
GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.
Comments
No comments yet.